Back to search results

A Study of BIIB144 for Healthy Adults

This study is looking at a new medicine called BIIB144, given through an IV (into a vein), for the very first time in people. Researchers want to understand how safe BIIB144 is and how your body processes it, compared to a placebo (a substance with no medicine). You could join if you are a healthy adult between 18 and 55 years old with a BMI (Body Mass Index) between 18 and 32. The main goal is to see if BIIB144 causes any side effects. This study aims to enroll 48 healthy volunteers.

Study design
This is an interventional study comparing BIIB144 to a placebo, involving 48 healthy adult participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your safety will be monitored for up to 280 days after receiving the study drug or placebo.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07662148

A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the Body of Healthy Adult Participants Ages 18 to 55 Years Old as Compared to a Placebo

Recruiting
PHASE1Ages 18–55InterventionalTreatment
Biogen
~48 participants
Updated 2026-07-27 on ClinicalTrials.gov
What's tested:BIIB144Placebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Measured over Up to Day 280

Conditions

Healthy Volunteer

Explore related trials

Healthy Volunteer

Where it's being run

1 sites across 1 states
Nevada1

Study leadership

  • Medical Director · STUDY_DIRECTOR · Biogen

Who to contact

US Biogen Clinical Trial Center
[email protected]
866-633-4636
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have a body mass index (BMI) between 18 and 32 kilograms per square metre (kg/m\^2), inclusive, at Screening.
Must be in good health as determined by the Investigator, based on medical history and Screening evaluations.

Exclusion

History of any clinically significant cardiac, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease, or other major disease, as determined by the Investigator.
History of severe allergic or anaphylactic reactions, or of any allergic reactions that in the opinion of the Investigator are likely to be exacerbated by any component of the study treatment.
History of, or ongoing, malignant disease, including solid tumors and hematologic malignancies (with the exception of basal cell carcinomas and squamous cell carcinomas that have been completely excised and considered cured at least 1 year prior to Day -1).
History of, or positive test result at Screening for, human immunodeficiency virus (HIV).
Any live or attenuated immunization or vaccination given within 14 days prior to Screening, between Screening and Day -1, or planned to be given during the study period.

What this trial measures

  • Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Up to Day 280